Blood salvage autotransfusion during transplantation for hepatocarcinoma: does it increase the risk of neoplastic recurrence?
Article first published online: 12 OCT 2005
Volume 18, Issue 11, pages 1236–1239, November 2005
How to Cite
Muscari, F., Suc, B., Vigouroux, D., Duffas, J.-P., Migueres, I., Mathieu, A., Lavayssiere, L., Rostaing, L. and Fourtanier, G. (2005), Blood salvage autotransfusion during transplantation for hepatocarcinoma: does it increase the risk of neoplastic recurrence?. Transplant International, 18: 1236–1239. doi: 10.1111/j.1432-2277.2005.00207.x
- Issue published online: 12 OCT 2005
- Article first published online: 12 OCT 2005
- Received: 28 May 2004 Revision requested: 21 June 2005 Accepted: 26 July 2005
- neoplastic recurrence;
Impact of intraoperative blood salvage autotransfusion (IBSA) on neoplastic recurrence. during liver transplantations for hepatocellular carcinoma (LT-HCC). Between January 1989 and February 2003, 16 patients received a LT-HCC without IBSA. This group was compared with 31 patients who received the same surgical procedure during the same period, but with IBSA. Data were prospectively collected. All patients had at least a 1-year postoperative follow up. Pairing was made according to the size of the largest nodule. The percentage of recurrence observed in the two groups was similar: 6.4% in the IBSA group vs. 6.3% in the group without IBSA. The median amount of transfused salvage blood was 1558 ml. The differences observed between the two groups concerned the Child score which was A in 58% patients of the IBSA group vs. 80% in the other group; the percentage of severe portal hypertension was 55% in the IBSA group vs. 31%; the median number of packed red blood cell units transfused intraoperatively was 7 in the IBSA group vs. 0, and the median number of frozen fresh plasma units transfused intraoperatively was 11 in the IBSA group vs. 4.5. It appears that IBSA, essentially used during the most haemorrhagic transplantations, could be used in the case of HCC because it does not modify the risk of neoplastic recurrence.